Navigation Links
NOVIS Announces Appointment of John J. Arlotta as Chairman
Date:10/23/2008

MIAMI, Oct. 23 /PRNewswire/ -- NOVIS Pharmaceuticals, Inc. today announced that healthcare industry veteran John J. Arlotta has been appointed Chairman of the Board. The appointment was announced during the most recent NOVIS Board of Directors meeting and is effective immediately.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081023/CLTH043LOGO )

"I am very excited to take on this role at NOVIS, and I look forward to helping the company achieve its aggressive strategic goals," said Mr. Arlotta. He added, "I am also very impressed with the management team that has been assembled at NOVIS, and I am excited to have the opportunity to assist them in achieving their vision for the company."

Thomas E. Burke III, President and CEO of NOVIS, said, "We are thrilled and honored to have John join our team. John's career has been exemplified by dramatic growth and an unwavering commitment to patient safety and customer service. I look forward to working with John as we create new partnerships, expand our product line, and further establish NOVIS as the vendor of choice for specialty therapeutics."

Mr. Arlotta has more than 30 years experience in the pharmacy services industry, most recently as Chairman, President and CEO of Coram Inc., a leading provider of specialty infusion and pharmacy distribution services that was acquired by Apria Healthcare Group in December 2007. Previously, he served as the President and CEO of NeighborCare, a Baltimore based public company and provider of pharmaceutical products and services to nursing homes. Mr. Arlotta's experience also includes five years as President and COO of Caremark Rx, ten years as owner and manager of HealthCall, and fifteen years at Baxter International. Mr. Arlotta is a graduate of the University of Notre Dame, is married with three adult children and currently lives in Denver, Colorado. In 2008, Mr. Arlotta purchased the Minnesota Swarm professional indoor lacrosse franchise.

About NOVIS Pharmaceuticals, Inc.

NOVIS Pharmaceuticals is a leading distributor of specialty therapeutics. Through superior customer service and innovative technology solutions, the company provides safe, timely and economical access to critical medications. Based in Miami, FL, and supported by strategically located centers throughout the U.S. and Puerto Rico, NOVIS is a privately held company. For more information, please visit http://www.novispharma.com .


'/>"/>
SOURCE NOVIS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. Renovis Reports Third Quarter 2007 Financial Results
3. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
4. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
5. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
6. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
7. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
8. Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec
9. Renovis Stockholders Approve Acquisition by Evotec
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):